BioStem director converts 5,094 RSUs into shares
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) director Kenneth Howard Warrington Jr reported an exercise of 5,094 Restricted Stock Units into an equal number of shares of common stock on 2026-08-27. The derivative RSUs were disposed and 5,094 common shares were acquired, bringing his direct common stock holdings to 32,234 shares. He also reports fully vested stock options and additional unvested RSUs that may convert into common stock over time.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,094 shares
Net Buy
4 txns
Insider
WARRINGTON KENNETH HOWARD JR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F2, F4 | 5,094 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,094 | $0.00 | $0.00 |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Restricted Stock Units F2, F3 | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 8,467 shares (Direct);
Common Stock — 32,234 shares (Direct);
Stock Options (Right to Buy) — 7,462 shares (Direct)
Footnotes (4)
- F1. These options are fully vested and exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F3. These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
- F4. These restricted stock units vested quarterly over the year following the grant date (August 27, 2025).
Key Figures
RSUs exercised: 5,094 units
Common shares acquired: 5,094 shares
Common stock holdings after transaction: 32,234 shares
+3 more
6 metrics
RSUs exercised
5,094 units
Restricted Stock Units converted into common stock on 2026-08-27
Common shares acquired
5,094 shares
Common stock received from RSU exercise on 2026-08-27
Common stock holdings after transaction
32,234 shares
Direct ownership of BioStem Technologies common stock following the Form 4 transaction
Stock options exercise price
$1.80 per share
Fully vested options to buy BioStem Technologies common stock expiring 2032-03-29
Underlying shares for stock options
7,462 shares
Common shares underlying fully vested stock options expiring 2032-03-29
Underlying shares for remaining RSUs
8,467 shares
Common shares underlying Restricted Stock Units vesting quarterly over three years from 2024-09-15
Key Terms
Restricted Stock Units, Stock Options (Right to Buy), contingent right, vest in equal quarterly installments
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an exercise price of 1.8000"
contingent right financial
"represents a contingent right to receive one share of the issuer's common"
vest in equal quarterly installments financial
"These restricted stock units vest in equal quarterly installments over three years"
FAQ
What insider transaction did BSEM director Kenneth Warrington report on this Form 4?
He reported exercising 5,094 Restricted Stock Units into 5,094 shares of common stock of BioStem Technologies, Inc. on 2026-08-27, reflecting a derivative exercise/conversion rather than an open-market purchase or sale.
What happened to the 5,094 Restricted Stock Units reported for BSEM on 2026-08-27?
On 2026-08-27, 5,094 Restricted Stock Units were reported as disposed of through an exercise or conversion into 5,094 shares of BioStem Technologies common stock, with a reported per-unit price of $0.00 for the derivative line.
What stock options does Kenneth Warrington still have in BSEM after this Form 4?
He reports stock options with an exercise price of $1.80 per share, expiring on 2032-03-29, covering 7,462 underlying shares of common stock, and noted as fully vested and exercisable in the footnotes.
Were Kenneth Warrington’s BSEM transactions reported under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not checked, and there is no footnote stating that the 2026-08-27 transactions were made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
